Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features

Lina van der Straten(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Anton W. Langerak(Erasmus MC), Paul J. Hengeveld(Erasmus MC)

Frontiers in Oncology

December 9, 2021

10.3389/fonc.2021.780085

Cited by 9

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

|Leukemia|2003|3k

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2018|907

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

|Journal of Clinical Oncology|2021|630

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2020|568

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

|Leukemia|2019|260